Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A sterile, nonpyrogenic, isotonic **multiple-electrolyte intravenous solution** containing sodium gluconate, potassium chloride, sodium acetate, magnesium chloride, and sodium chloride, marketed most commonly as **Plasma-Lyte A** and **Plasma-Lyte 148**. It is used in adults and pediatric patients as a source of water and electrolytes for hydration, for correction of dehydration and electrolyte disturbances, and as an alkalinizing agent. Its pharmacologic effect is replacement of extracellular fluid electrolytes together with support of **acid-base homeostasis**; acetate and gluconate are metabolized to bicarbonate precursors and thereby help buffer metabolic acidosis. This product is an approved pharmaceutical combination of inorganic salts rather than a biologic, oncology asset, or antimicrobial drug. A related electrolyte irrigating solution exists, but the injectable drug of interest here is the balanced IV crystalloid formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium gluconate + potassium chloride + sodium acetate + magnesium chloride + sodium chloride.